{"id":"doxycycline-post-exposure-prophylaxis","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Photosensitivity"},{"rate":"5-10%","effect":"Nausea and vomiting"},{"rate":"1-5%","effect":"Esophageal irritation"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Vaginal yeast infection"},{"rate":"1-3%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxycycline is a tetracycline antibiotic that works by inhibiting bacterial protein synthesis, making it effective as post-exposure prophylaxis against susceptible organisms. When used prophylactically after potential exposure to pathogens such as Bacillus anthracis (anthrax) or other bacteria, it prevents infection establishment by suppressing bacterial growth before clinical disease develops. The drug is bacteriostatic, meaning it stops bacterial replication rather than directly killing the organisms.","oneSentence":"Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing pathogenic bacteria from multiplying after potential exposure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:00.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Post-exposure prophylaxis for anthrax (Bacillus anthracis)"},{"name":"Post-exposure prophylaxis for other susceptible bacterial pathogens"}]},"trialDetails":[{"nctId":"NCT07397403","phase":"PHASE4","title":"The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand.","status":"RECRUITING","sponsor":"Bangrak STIs Center","startDate":"2025-10-06","conditions":"Syphilis Infection, Gonorrhea, Chlamydia","enrollment":400},{"nctId":"NCT07361926","phase":"NA","title":"Sexual Health Access at Retail Pharmacies: Advancing Pharmacy-based Delivery of Primary STI and HIV Prevention for Cisgender Women","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-05","conditions":"Sexually Transmitted Infections (Not HIV or Hepatitis), HIV Infections","enrollment":720},{"nctId":"NCT07215325","phase":"PHASE4","title":"Got Doxy- 'Flipping the Script' on STI PEP","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-22","conditions":"Sexually Transmitted Infections (STI)","enrollment":200},{"nctId":"NCT06468462","phase":"PHASE4","title":"Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-10-29","conditions":"Gonorrhea Male, Chlamydia (Male), Syphilis Male","enrollment":2900},{"nctId":"NCT05853120","phase":"PHASE4","title":"Doxy-Post-exposure Prophylaxis","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-05-31","conditions":"Sexually Transmitted Diseases","enrollment":45},{"nctId":"NCT04067011","phase":"PHASE2","title":"Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2019-08-12","conditions":"Anthrax","enrollment":210},{"nctId":"NCT05072093","phase":"PHASE4","title":"Parrying the Pitfalls of PrEP: Project PEACH","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-11-20","conditions":"HIV, STI","enrollment":240},{"nctId":"NCT06188442","phase":"PHASE4","title":"Superiority of On-demand PrEP Versus PEP on Using Doxycycline for Preventing STI in MSM","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-03-29","conditions":"Sexually Transmitted Diseases, Bacterial, Syphilis, Gonorrhea","enrollment":300},{"nctId":"NCT06778083","phase":"","title":"STI Prophylaxis and Emergence of Antimicrobial Resistance","status":"RECRUITING","sponsor":"University College, London","startDate":"2025-02-10","conditions":"Sexually Transmitted Infection (STI) Prevention, Antibiotic Prophylaxis, Antibiotic Resistance, Bacterial","enrollment":108},{"nctId":"NCT00237016","phase":"PHASE2, PHASE3","title":"Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever","status":"COMPLETED","sponsor":"Medical Corps, Israel Defense Force","startDate":"2002-04","conditions":"Relapsing Fever, Tick-borne, Jarisch Herxheimer Reaction","enrollment":140},{"nctId":"NCT06007534","phase":"NA","title":"Pharmacokinetic Characterization of a Single 200 mg Dose of Doxycycline in Post-exposure Prophylaxis (PEP) of Sexually Transmitted Infections in Different Biological Compartments","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-25","conditions":"Post-exposure Prophylaxis, Sexually Transmitted Diseases, Doxycycline","enrollment":25},{"nctId":"NCT04762134","phase":"NA","title":"Doxycycline Intervention for Bacterial STI ChemoprOphylaxis (DISCO)","status":"RECRUITING","sponsor":"Jonathan Troy Grennan","startDate":"2023-06-02","conditions":"Bacterial Sexually Transmitted Diseases","enrollment":560},{"nctId":"NCT02844634","phase":"PHASE4","title":"Tenofovir/Emtricitabine With Doxycycline for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative MSM","status":"COMPLETED","sponsor":"British Columbia Centre for Disease Control","startDate":"2018-05-15","conditions":"HIV, Syphilis","enrollment":52},{"nctId":"NCT04597424","phase":"PHASE3","title":"Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-01-19","conditions":"Unsafe Sex, Risk-Taking","enrollment":556},{"nctId":"NCT03980223","phase":"PHASE4","title":"Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-11-26","conditions":"Gonorrhea, Chlamydia, Syphilis","enrollment":641},{"nctId":"NCT04050540","phase":"PHASE4","title":"Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-02-05","conditions":"HIV Infections, HIV/AIDS, Neisseria Gonorrheae Infection","enrollment":449},{"nctId":"NCT04860505","phase":"PHASE4","title":"Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-05-20","conditions":"Sexually Transmitted Diseases","enrollment":20},{"nctId":"NCT01874860","phase":"PHASE2","title":"Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2013-08","conditions":"Colorectal Cancer, Head and Neck Cancer","enrollment":24},{"nctId":"NCT02564471","phase":"PHASE4","title":"Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2016-11-11","conditions":"Rabies","enrollment":103}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":123,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["doxyPEP"],"phase":"marketed","status":"active","brandName":"Doxycycline post-exposure prophylaxis","genericName":"Doxycycline post-exposure prophylaxis","companyName":"University of Washington","companyId":"university-of-washington","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxycycline is used as post-exposure prophylaxis, as indicated by ClinicalTrials.gov in the \"Doxy-PEP: Dose-Ranging Study of Persons Receiving Doxycycline\" study. As a small molecule, doxycycline works through its mechanism of action, which is not specified in the provided facts, but is documented in ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}